Natera (NASDAQ:NTRA) Price Target Raised to $500.00

Natera (NASDAQ:NTRA) had its target price boosted by Canaccord Genuity Group from $375.00 to $500.00 in a report issued on Monday morning, MarketBeat reports. They currently have a buy rating on the medical research company’s stock.

Several other analysts have also issued reports on NTRA. Citigroup boosted their price objective on shares of Natera from $365.00 to $480.00 and gave the company a “buy” rating in a report on Tuesday, October 6th. Piper Sandler upped their target price on shares of Natera from $249.00 to $363.50 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Guggenheim increased their target price on shares of Natera from $360.00 to $475.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research report on Thursday, October 15th. Finally, Royal Bank Of Canada lifted their price target on shares of Natera from $350.00 to $460.00 and gave the company an “outperform” rating in a research report on Friday, September 25th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $374.64.

Natera Price Performance

NTRA stock opened at $413.38 on Monday. The business has a fifty day moving average of $363.64 and a two-hundred day moving average of $280.16. Natera has a 52-week low of $181.00 and a 52-week high of $437.41.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The company had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. During the same quarter in the previous year, the business earned ($0.74) earnings per share. The company’s revenue for the quarter was up 37.7% on a year-over-year basis. Sell-side analysts forecast that Natera will post -1.05 EPS for the current fiscal year.

Insider Transactions at Natera

In related news, insider Solomon Moshkevich sold 15,160 shares of the stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $326.89, for a total transaction of $4,955,652.40. Following the transaction, the insider owned 110,859 shares of the company’s stock, valued at approximately $36,238,698.51. This represents a 12.03% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Brophy sold 2,419 shares of the stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $253.96, for a total transaction of $614,329.24. Following the sale, the chief financial officer directly owned 54,295 shares in the company, valued at $13,788,758.20. This represents a 4.27% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 52,985 shares of company stock valued at $16,119,137. Corporate insiders own 5.05% of the company’s stock.

Institutional Trading of Natera

Hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new position in shares of Natera during the second quarter worth about $2,962,770,000. K.J. Harrison & Partners Inc purchased a new stake in shares of Natera during the second quarter worth approximately $5,117,000. Abbot Financial Management Inc. purchased a new stake in shares of Natera during the second quarter worth approximately $1,537,000. Eagle Health Investments LP purchased a new stake in shares of Natera during the second quarter worth approximately $4,302,000. Finally, BlueCrest Capital Management Ltd acquired a new stake in Natera in the second quarter valued at approximately $11,695,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.